Controversies in treatment selection for patients with equivocal ER and HER2 results

Research output: Contribution to journalArticle

Abstract

Formally, the term "equivocal" should not be used when reporting results of the assessment of ER status, but controversies exist about the prognostic and predictive value of a low ER expression (i.e. 1-9% positive cells) in breast cancer (so called ER-poor tumors). Because of the rarity of these cases, prospective clinical trials have not been conducted (and are unlikely to be conducted in the future) to define the optimal treatment strategy for the small subset of patients with ER-poor breast cancer. Therefore, the only available data stem from retrospective subgroup analyses of randomized clinical trials or from clinical datasets of individual Institutions. The still unanswered question is whether these tumors are responsive to endocrine treatment, and what is the magnitude of the benefit of endocrine interventions for patients with ER-poor breast cancer. Since a potentially life-saving benefit from empirical adjuvant endocrine therapy cannot be excluded, the safest clinical approach may be to consider both adjuvant endocrine therapy and chemotherapy in this rare subset of patients. Testing for HER2 overexpression by immunohistochemistry or for gene amplification by in situ hybridization techniques may end up with equivocal results. Patients with equivocal HER2 status were not eligible for the pivotal clinical trials of adjuvant trastuzumab, and the possible benefit of HER2-targeted therapies for this subset of patients is unknown. The clinical results of the NSABP B47 clinical trial will eventually clarify if trastuzumab is effective, and what is the magnitude of its effect, in this patient population.

Original languageEnglish
JournalBreast
DOIs
Publication statusPublished - 2017

Fingerprint

Patient Selection
Clinical Trials
Breast Neoplasms
Therapeutics
Gene Amplification
In Situ Hybridization
Neoplasms
Randomized Controlled Trials
Immunohistochemistry
Drug Therapy
Population
Trastuzumab

Keywords

  • Anti-HER2 therapies
  • Endocrine responsiveness
  • Estrogen receptor-poor breast cancer
  • HER2 equivocal results

ASJC Scopus subject areas

  • Surgery

Cite this

@article{6b8f1e1ff750411595cc4ed5559e5318,
title = "Controversies in treatment selection for patients with equivocal ER and HER2 results",
abstract = "Formally, the term {"}equivocal{"} should not be used when reporting results of the assessment of ER status, but controversies exist about the prognostic and predictive value of a low ER expression (i.e. 1-9{\%} positive cells) in breast cancer (so called ER-poor tumors). Because of the rarity of these cases, prospective clinical trials have not been conducted (and are unlikely to be conducted in the future) to define the optimal treatment strategy for the small subset of patients with ER-poor breast cancer. Therefore, the only available data stem from retrospective subgroup analyses of randomized clinical trials or from clinical datasets of individual Institutions. The still unanswered question is whether these tumors are responsive to endocrine treatment, and what is the magnitude of the benefit of endocrine interventions for patients with ER-poor breast cancer. Since a potentially life-saving benefit from empirical adjuvant endocrine therapy cannot be excluded, the safest clinical approach may be to consider both adjuvant endocrine therapy and chemotherapy in this rare subset of patients. Testing for HER2 overexpression by immunohistochemistry or for gene amplification by in situ hybridization techniques may end up with equivocal results. Patients with equivocal HER2 status were not eligible for the pivotal clinical trials of adjuvant trastuzumab, and the possible benefit of HER2-targeted therapies for this subset of patients is unknown. The clinical results of the NSABP B47 clinical trial will eventually clarify if trastuzumab is effective, and what is the magnitude of its effect, in this patient population.",
keywords = "Anti-HER2 therapies, Endocrine responsiveness, Estrogen receptor-poor breast cancer, HER2 equivocal results",
author = "Giuseppe Viale",
year = "2017",
doi = "10.1016/j.breast.2017.06.030",
language = "English",
journal = "Breast",
issn = "0960-9776",
publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - Controversies in treatment selection for patients with equivocal ER and HER2 results

AU - Viale, Giuseppe

PY - 2017

Y1 - 2017

N2 - Formally, the term "equivocal" should not be used when reporting results of the assessment of ER status, but controversies exist about the prognostic and predictive value of a low ER expression (i.e. 1-9% positive cells) in breast cancer (so called ER-poor tumors). Because of the rarity of these cases, prospective clinical trials have not been conducted (and are unlikely to be conducted in the future) to define the optimal treatment strategy for the small subset of patients with ER-poor breast cancer. Therefore, the only available data stem from retrospective subgroup analyses of randomized clinical trials or from clinical datasets of individual Institutions. The still unanswered question is whether these tumors are responsive to endocrine treatment, and what is the magnitude of the benefit of endocrine interventions for patients with ER-poor breast cancer. Since a potentially life-saving benefit from empirical adjuvant endocrine therapy cannot be excluded, the safest clinical approach may be to consider both adjuvant endocrine therapy and chemotherapy in this rare subset of patients. Testing for HER2 overexpression by immunohistochemistry or for gene amplification by in situ hybridization techniques may end up with equivocal results. Patients with equivocal HER2 status were not eligible for the pivotal clinical trials of adjuvant trastuzumab, and the possible benefit of HER2-targeted therapies for this subset of patients is unknown. The clinical results of the NSABP B47 clinical trial will eventually clarify if trastuzumab is effective, and what is the magnitude of its effect, in this patient population.

AB - Formally, the term "equivocal" should not be used when reporting results of the assessment of ER status, but controversies exist about the prognostic and predictive value of a low ER expression (i.e. 1-9% positive cells) in breast cancer (so called ER-poor tumors). Because of the rarity of these cases, prospective clinical trials have not been conducted (and are unlikely to be conducted in the future) to define the optimal treatment strategy for the small subset of patients with ER-poor breast cancer. Therefore, the only available data stem from retrospective subgroup analyses of randomized clinical trials or from clinical datasets of individual Institutions. The still unanswered question is whether these tumors are responsive to endocrine treatment, and what is the magnitude of the benefit of endocrine interventions for patients with ER-poor breast cancer. Since a potentially life-saving benefit from empirical adjuvant endocrine therapy cannot be excluded, the safest clinical approach may be to consider both adjuvant endocrine therapy and chemotherapy in this rare subset of patients. Testing for HER2 overexpression by immunohistochemistry or for gene amplification by in situ hybridization techniques may end up with equivocal results. Patients with equivocal HER2 status were not eligible for the pivotal clinical trials of adjuvant trastuzumab, and the possible benefit of HER2-targeted therapies for this subset of patients is unknown. The clinical results of the NSABP B47 clinical trial will eventually clarify if trastuzumab is effective, and what is the magnitude of its effect, in this patient population.

KW - Anti-HER2 therapies

KW - Endocrine responsiveness

KW - Estrogen receptor-poor breast cancer

KW - HER2 equivocal results

UR - http://www.scopus.com/inward/record.url?scp=85021792660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021792660&partnerID=8YFLogxK

U2 - 10.1016/j.breast.2017.06.030

DO - 10.1016/j.breast.2017.06.030

M3 - Article

JO - Breast

JF - Breast

SN - 0960-9776

ER -